Page last updated: 2024-09-03

elacridar and Lung Neoplasms

elacridar has been researched along with Lung Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anderson, R; Jooné, G; Van Rensburg, CE1
Beijnen, JH; Jewell, RC; Koopman, FJ; Malingré, MM; Paul, EM; Rosing, H; Schellens, JH; Ten Bokkel Huinink, WW1

Trials

1 trial(s) available for elacridar and Lung Neoplasms

ArticleYear
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    British journal of cancer, 2001, Jan-05, Volume: 84, Issue:1

    Topics: Acridines; Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Tetrahydroisoquinolines

2001

Other Studies

1 other study(ies) available for elacridar and Lung Neoplasms

ArticleYear
Alpha-tocopherol antagonizes the multidrug-resistance-reversal activity of cyclosporin A, verapamil, GF120918, clofazimine and B669.
    Cancer letters, 1998, May-15, Volume: 127, Issue:1-2

    Topics: Acridines; Cell Death; Clofazimine; Cyclosporine; Drug Resistance, Multiple; Humans; Isoquinolines; Lung Neoplasms; Tetrahydroisoquinolines; Tumor Cells, Cultured; Verapamil; Vinblastine; Vitamin E

1998